About the Company
We do not have any company description for Vivos Therapeutics, Inc. at the moment.
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & Apparatus
Employees
82
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Vivos Therapeutics, Inc.
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4. ...
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing ...
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue ... - Nasdaq
Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $3.05 per share a year ago.
Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today
Vivos Therapeutics Inc VVOS shares are trading lower by 26.1% to $3.05 during Thursday’s session after the company announced a $4.3 million registered offering of 1.36 million shares of common ...
Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ: VVOS) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Kirk Huntsman - Chariman & CEO Brad Amman - CFO Conference Call ...
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2023 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ: VVOS) Q4 2023 Earnings Call Transcript March 28, 2024 Vivos Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-3.05 EPS, expectations were $-1.9.
Vivos Therapeutics stock soars as sleep apnea device gets regulatory ...
Vivos Therapeutics Inc. shares VVOS jumped more than 270% Wednesday after the medical-device maker got regulatory clearance for removable oral appliances that treat obstructive sleep apnea.
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue ... - Nasdaq
Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $1.63 per share a year ago.
Vivos Therapeutics Delays Q2 2025 10-Q Filing
Vivos Therapeutics ( ($VVOS) ) has released a notification of late filing. Vivos Therapeutics, Inc. has announced a delay in filing its Form 10-Q ...
Vivos Therapeutics, Inc. (VVOS) Q3 2023 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2023 Earnings Conference Call November 14, 2023 5:00 PM ETCompany ParticipantsJulie Gannon - Investor Relations ...
Similar Companies
Loading the latest forecasts...